Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/06—Antiabortive agents; Labour repressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems

Definitions

• the present invention relates to compounds useful as inhibitors of Janus kinases (JAK) and Rho-associated coiled-coil forming protein serine/threonine kinases (ROCK).
• the invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
• JAK2 has been implicated in myeloproliferative disorders, which include polycythemia vera, essential thrombocythemia, chronic idiopathic myelofibrosis, myeloid metaplasia with myelofibrosis, chronic myeloid leukemia, chronic myelomonocytic leukemia, chronic eosinophilic leukemia, hypereosinophilic syndrome and systematic mast cell disease.
• R 1 , R 2 , R 3 , Z and Q are as defined below.
• substituent When more than one position in a given structure can be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at each position. [ 0109 ] As described herein, when the term “optionally substituted” precedes a list, said term refers to all of the subsequent substitutable groups in that list. If a substituent radical or structure is not identified or defined as “optionally substituted", the substituent radical or structure is unsubstituted. For example, if X is halogen; optionally substituted C 1-3 alkyl or phenyl; X may be either optionally substituted alkyl or optionally substituted phenyl.
• aliphatic or "aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation. Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and In yet other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms.
• Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, or alkynyl groups. Further examples of aliphatic groups include methyl, ethyl, propyl, butyl, isopropyl, isobutyl, vinyl, and sec-butyl.
• cycloaliphatic refers to a monocyclic C 3 -C 8 hydrocarbon or bicyclic C 8 -C 12 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule, and wherein any individual ring in said bicyclic ring system has 3-7 members.
• Suitable cycloaliphatic groups include, but are not limited to, cycloalkyl, cycloalkenyl, and cycloalkynyl. Further examples of aliphatic groups include cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cycloheptenyl.
• the "heterocycle”, “heterocyclyl”, “heterocycloaliphatic”, or “heterocyclic” group has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the system contains 3 to 7 ring members.
• heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon, including any oxidized form of nitrogen, sulfur, phosphorus, or silicon, the quaternized form of any basic nitrogen, or a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl).
• alkoxy refers to an alkyl group, as previously defined, attached to the principal carbon chain through an oxygen (“alkoxy”) or sulfur (“thioalkyl”) atom.
• haloalkyl means alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms.
• halogen means F, Cl, Br, or I.
• aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic, bicyclic, and tricyclic carbocyclic ring systems having a total of six to fourteen ring members, wherein at least one ring in the system is aromatic, wherein each ring in the system contains 3 to 7 ring members and that has a single point of attachment to the rest of the molecule.
• aryl may be used interchangeably with the term “aryl ring”. Examples of aryl rings would include phenyl, naphthyl, and anthracene.
• heteroaryl used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, wherein each ring in the system contains 3 to 7 ring members and that has a single point of attachment to the rest of the molec'ule.
• heteroaryl may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.
• Further examples of heteroaryl rings include the following monocycles :
• an aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents. Suitable substituents on the unsaturated carbon atom of an aryl or heteroaryl group are selected from those listed in the definition of J Q , J R , J v , J u and J x below.
• Optional substituents on the aliphatic group or the phenyl ring of R + are selected from NH 2 , NH(C 1-4 aliphatic), N(C 1-4 aliphatic) 2 , halogen, C 1-4 aliphatic, OH, 0(C 1-4 aliphatic), NO 2 , CN, CO 2 H, CO 2 (C 1-4 aliphatic), O(halo C 1-4 aliphatic), or halo(C 1-4 aliphatic), wherein each of the foregoing C 1-4 aliphatic groups of R + is unsubstituted. [ 0125 ] As detailed above, in some embodiments, two independent occurrences of
• R 0 (or R + , or any other variable similarly defined herein), may be taken together with the atom(s) to which each variable is bound to form a 5-8-membered heterocyclyl, aryl, or heteroaryl ring or a 3-8-membered cycloalkyl ring.
• Exemplary rings that are formed when two independent occurrences of R 0 (or R + , or any other variable similarly defined herein) are taken together with the atom(s) to which each variable is bound include, but are not limited to the following: a) two independent occurrences of R 0 (or R + , or any other variable similarly defined herein) that are bound to the same atom and are taken together with that atom to form a ring, for example, N(R°) 2 , where both occurrences of R 0 are taken together with the nitrogen atom to form a piperidin-1-yl, piperazin-1-yl, or morpholin-4-yl group; and b) two independent occurrences of R 0 (or R + , or any other variable similarly defined herein) that are bound to different atoms and are taken together with both of those atoms to form a ring, for example where a phenyl group is substituted
• an alkyl or aliphatic chain can be optionally interrupted with another atom or group. This means that a methylene unit of the alkyl or aliphatic chain is optionally replaced with said other atom or group.
• Optional interruptions can occur both within the chain and at either end of the chain; i.e. both at the point of attachment and/or also at the terminal end.
• Two optional replacements can also be adjacent to each other within a chain so long as it results in a chemically stable compound. Unless otherwise specified, if the replacement or interruption occurs at the terminal end, the replacement atom is bound to an H on the terminal end. For example, if -CH 2 CH 2 CH 3 were optionally interrupted with -0-, the resulting compound could be -OCH 2 CH 3 , -CH 2 OCH 3 , or -CH 2 CH 2 OH.
• a bond drawn from a substituent to the center of one ring within a multiple-ring system represents substitution of the substituent at any substitutable position in any of the rings within the multiple ring system.
• Figure a represents possible substitution in any of the positions shown in Figure b.
• Figure a Figure b [0128] This also applies to multiple ring systems fused to optional ring systems (which would be represented by dotted lines).
• X is an optional substituent both for ring A and ring B.
• each substituent only represents substitution on the ring to which it is attached.
• Y is an optionally substituent for ring A only
• X is an optional substituent for ring B only.
• structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention.
• the present invention relates to a compound of formula I:
• Q is a 3-8 membered saturated, partially saturated, or unsaturated monocyclic ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur; or an 8-12 membered bicyclic ring having 0-6 heteroatoms selected from nitrogen, oxygen, or sulfur; wherein Q is optionally substituted with 1-10 occurrences of J Q ;
• R 1 is -(C 1-2 aliphatic) p -R 4 wherein each R 1 is optionally substituted with 1-3 occurrences of J;
• R 2 is -(C 1-2 aliphatic) d -R 5 wherein each R 1 is optionally substituted with 1-3 occurrences of J;
• R 3 is halogen, -CN, -NO 2 or -(U) m -X, wherein
• U is a C 1-6 aliphatic, wherein up to two methylene units are optionally and independently replaced by G u and wherein U is optionally substituted with 1-4 J u ;
• X is H, halogen, CN, NO 2 , S(O)R, SO 2 R, C 1-4 haloaliphatic, or a group selected from C 1-6 aliphatic, a C 3-1 O cycloaliphatic, C 6-1O aryl, 5-10 membered heteroaryl, 5-10 membered heterocyclyl; wherein said group is optionally substituted with 1-4 J x ;
• G u is -NH-, -NR-, -O-, -S-, -CO 2 -, -OC(O)-, -C(O)CO-, -C(O)-, -C(O)NH-,
• J Q is halogen, OCF 3 , -(Vn)-R", -(Vn)-CN, -(V n )-NO 2 , or -(V n )-(C 1-4 haloaliphatic), wherein J Q is not H;
• R" is H, or is an optionally substituted group selected from C 1-G aliphatic, C 3-10 cycloaliphatic, C 6-10 aryl, 5-10 membered heteroaryl, or 5-10 membered heterocyclyl; or two R" groups, on the same substituent or different substituents, together with the atom(s) to which each R" group is bound, form an optionally substituted 3-8 membered heterocyclyl; wherein each optionally substituted R" group is independently and optionally substituted with 1-6 occurrences of J R ;
• R is an optionally substituted group selected from C 1-6 aliphatic, C 3-1O cycloaliphatic, C 6- io aryl, 5-10 membered heteroaryl, or 5-10 membered heterocyclyl; or two R groups, on the same substituent or different substituents, together with the atom(s) to which each R group is bound, form an optionally substituted 3-8 membered heterocyclyl; wherein each R group is independently and optionally substituted with 1-4 occurrences of J ;
• J v , J u , J x , and J R are each independently selected from halogen, L, -(L n )-R ⁇ -(L n )-N(R) 2 , -(Ln)-SR', -(L n )-OR', -(L n )-(C 3-10 cycloaliphatic), -(Ln)-(C 6-10 aryl), -OU)-(S-IO membered heteroaryl), -(L n )-(5-10 membered heterocyclyl), oxo, C 1-4 haloalkoxy, C 1-4 haloalkyl, -(U)-NO 2 , -(Ln)-CN, -(Ln)-OH, -(L n )-CF 3 , -CO 2 R', -CO 2 H, -COR', -COH, -OC(O)R', or -NC(O
• R' is H or C 1-6 aliphatic; or two R' groups, together with the atom to which they are attached, optionally form a 3-6 membered cycloaliphatic or heterocyclyl, wherein said aliphatic, cycloaliphatic or heterocyclyl is optionally substituted with R*, - OR*, -SR*, -NO 2 , -CF 3 , -CN, -CO 2 R*, -COR*, OCOR*, NHCOR*, wherein R* is H or C 1-6 aliphatic;
• R 6 is selected from C 1-6 aliphatic, C 3-1O cycloaliphatic, C 6-1O aryl, 5-10 membered heteroaryl, or 5-10 membered heterocyclyl; or two R groups, on the same substituent or different substituents, together with the atom(s) to which each R 6 group is bound, form a 3-8 membered heterocyclyl;
• the invention provides a compound of formula I- a
• the invention provides a compound of formula I- b
• phenyl when R 1 and R 3 are H, R 2 is Me, and Z' is NH, then Q is not F ; when R 1 , R 2 and R 3 are H, and Z' is NH; then Q is not 3,5-difluoro phenyl, 4-amino phenyl, 4-nitro phenyl, 2-chloro-4-amino phenyl, 2-chloro-4-nitro phenyl, 3,4-
• R 1 is H, halogen, CN, NH 2 , NO 2 , CF 3 , CH 3 , NCH 3 , OCH 3 , or OH.
• R 1 is H, halogen, or CF 3 .
• R 1 is H.
• d is O.
• R 2 is H, halogen,
• R 2 is H, halogen, or CF 3 .
• R is H.
• both R 1 and R 2 are H.
• m is 0 and R 3 is H, halogen, -CN, -NO 2 or X.
• R 3 is H, halogen or C 1-3 aliphatic.
• R 3 is H or Cl.
• m is 1 and U is an optionally substituted C 1-3 aliphatic, wherein up to two methylene units are optionally replaced with 0-2 G u groups.
• G u is selected from -NH-, -NR-, -O-, -CO 2 -, -OC(O)- or -C(O)-.
• X is selected from H, C 1-6 aliphatic, halogen, CN, NO 2 , S(O) 0- 2 R, or C 1-4 haloalkyl.
• X is H, C 1-6 alkyl or halogen.
• X is H or Cl.
• R and R are H and R is H or Cl.
• Z is a bond and R 3 is selected from H, Cl, Br, F, -
• R 3 is selected from H, Cl, -Br, -CN, -COOH, -COOMe, - CONHR', -CON(Me) 2 , -CH 2 OH, -NO 2 , -NH 2 or an optionally substituted C 1 -C 4 aliphatic.
• R 3 is selected from Cl, -Br, -CN or an optionally substituted C 1 -C 4 aliphatic.
• R 3 is Cl.
• J u is selected from halogen, CN, NO 2 , C 1-
• haloalkyl OH, C 1-3 alkyl, -O-(C 1-2 alkyl), NH 2 , -NH-(C 1-2 alkyl), -N(C 1-2 alkyl) 2 , -O-(C 1-2 haloalkyl), or oxo.
• J x is selected from halogen, CN, NO 2 , C 1-
• haloalkyl OH, C 1-3 alkyl, -O-(C 1-2 alkyl), NH 2 , -NH-(C 1-2 alkyl), -N(Ci -2 alkyl) 2 , -O-(C 1-2 haloalkyl), or oxo.
• Q is a 5-10 membered aryl or heteroaryl ring optionally substituted with 1-5 J Q groups. In a further embodiment, Q is a 5-6 membered aryl or heteroaryl ring optionally substituted with 1-5 J Q groups. [0144 ] In another embodiment, Q is a 5-6 membered ring selected from:
• Q is a 6-membered ring selected from phenyl
• Q is phenyl (a), pyridyl (b), or pyrimidyl (c).
• Q is 2-pyridyl, 4-pyridyl, 2,6-pyrimidyl or phenyl.
• R and R are H.
• R 3 is H, halogen, or C 1-6 aliphatic.
• R 3 is H or Cl.
• Q is as described herein, Z is a bond. In a different embodiment, when Q is as described herein, Z is NH.
• Q is a 5-membered ring selected from pyrazolyl (h), thiophenyl (v), furanyl (u) or pyrrolyl (w).
• R 1 and R 2 are H.
• R 3 is H, halogen, or C 1-6 aliphatic.
• R 3 is H or Cl.
• Z is a bond. In a different embodiment, when Q is as described herein, Z is NH.
• Q is a 5-12 membered saturated or partially saturated monocyclic or bicyclic ring system optionally substituted with 1-5 J Q groups.
• Q is a 5-12 membered fully saturated or partially saturated monocyclic or bicyclic cycloaliphatic ring system.
• Q is a mono-unsaturated ring as represented by formula II:
• Q is a 5-6 membered fully saturated or partially saturated monocyclic cycloaliphatic ring system.
• Q is a 5-8 membered partially saturated heterocyclyl ring.
• Q is a 5-6 membered heterocyclyl containing 1-2 nitrogen atoms.
• Q contains 1 nitrogen atom.
• Q is the ring represented in formula III:
• Z is a bond or NH.
• R 1 and R 2 are H.
• R 3 is H, halogen, or C 1-6 aliphatic.
• R 3 is H or Cl.
• each occurrence of J Q is independently selected from R", -CH 2 R", halogen, CN, NO 2 , -COR", -COR 8 R", - N(R')R", -CH 2 N(R')R", -OR", -CH 2 OR", -SR", -CH 2 SR", -C(O)OR", -NR'COR", - NR 5 COR 8 R", -NR'COOR", -NR 5 COOR 8 R", -CON(R')R", -C0N(R')R 8 R", - SO 2 N(R')R", -SO 2 N(R')R 8 R", -C0N(R')R 8 N(R')R", -OR 8 OR", -OR 8 N(R')R", - NR'CH(R 8 )R", -NR'CH(R 8 )C(O)OR", -N(R')R 8 R
• each occurrence of J ⁇ is independently selected from R", -CH 2 R", halogen, -CN, -NO 2 , -N(R')R", -CH 2 N(R')R", -OR", -CH 2 OR", -SR", -CH 2 SR", -COOR", -NR'COR", -NR 5 COCH 2 R", -NR'CO(CH 2 ) 2 R", -NR'COOR", - C0N(R')R", -SO 2 N(R')R", -CONR'(CH 2 ) 2 N(R 5 )R", -CONR(CH 2 ) 3 N(R')R", - CONR'(CH 2 ) 4 N(R') R” , ⁇ O(CH 2 ) 2 OR", O(CH 2 ) 3 OR", O(CH 2 ) 4 OR", -O(CH 2 ) 2 N(R')R", - O(CH 2 ) 2 OR", O(CH 2 )
• R' or two occurrences of R' are taken together with the nitrogen atom to which they are bound to form an optionally substituted 3-10-membered monocyclic or bicyclic heterocyclic ring selected from:
• R 7 is independently R', -CH 2 R', halogen, , CH 2 CH, CN, NO 2 , -N(R') 2 , -CH 2 N(R') 2 , -OR', -CH 2 OR', -SR', -CH 2 SR', - COOR', -COR', -NR 9 COR', -NR 9 COOR', -CON(R') 2 , -SO 2 N(R') 2 , -NR 9 SO 2 R', - CONR 9 (CH 2 ) 2 N(R 9 )R', -CONR 9 (CH 2 ) 3 N(R 9 )R ⁇ -CONR 9 (CH 2 ) 4 N(R 9 )R', -O(CH 2 ) 2 OR', O(CH 2 ) 3 OR', O(CH 2 ) 4 OR', -O(CH 2 ) 2 N(R
• J Q is -V-R", -V-CN, -V-NO 2 , or -V-
• V is C 1-6 alkyl, wherein up to two methylene units are replaced by G v wherein G v is selected from -NH-, -NR-, -O-, -S-, -
• V is a Q ⁇ alltyl wherein zero methylene units are replaced by G v .
• V is CH 2 .
• V is substituted with 2 J v groups; wherein J v is C 1-3 alkyl or two J v groups, together with the methylene unit to which they are attached, form a 3-6 membered cycloalkyl ring.
• one methylene unit of V is replaced by G v .
• V is a Qalkyl, wherein one methylene unit is replaced by G v .
• G v is bonded directly to R".
• J v is selected from halogen, NH 2 , NO 2 , CN, OH,
• Q is 5-10 membered aryl or heteroaryl optionally substituted with 0-4 occurrences of J Q and J Q is halogen, OCF 3 , -(V n )-CN, -(V n )-N0 2 , or
• J Q is -(V n )-R" and V is a C 2-10 aliphatic, wherein up to three methylene units are replaced by G v , wherein G v is selected from -NH-, -NR-, -0-, -S-, -CO 2 -, -OC(O)-, -C(O)CO-, -C(O)-, -C(O)NH-, -C(O)NR-,
• R 5 is H, halogen, CN, NH 2 , NO 2 , CF 3 , C 1-3 aliphatic, cyclopropyl, NCH 3 , OCH 3 ,
• J v , J u , J x , and J R are each independently selected from halogen, L, -(L n )-R', -(L n )-N(R ) 2 , -(Ln)-SR', -(Ln)-OR', -(Ln)-(C 3 -I 0 cycloaliphatic), -(Ln)-(C 6-10 aryl), -(Ln)-(S-IO membered heteroaryl), -(L n )-(5-10 membered heterocyclyl), oxo, C 1-4 haloalkoxy, C ⁇ haloalkyl, -(Ln)-NO 2 , -(Ln)-CN, -(Ln)-OH, -(Ln)-CF 3 , -CO 2 R', -CO 2 H, -COR', -COH, -OC(O)R', or -NC(
• compositions of this invention may be administered in the form of suppositories for rectal administration.
• suppositories for rectal administration.
• suppositories can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
• suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
• compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
• the pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
• Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
• the pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
• the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
• adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
• injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
• the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
• compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
• suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
• Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
• the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar—agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay
• Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
• the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
• the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
• buffering agents include polymeric substances and waxes.
• Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
• the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
• Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention.
• the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
• Such dosage forms can be made by dissolving or dispensing the compound in the proper medium.
• Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
• agents the inhibitors of this invention may also be combined with include, without limitation: treatments for Alzheimer's Disease such as Aricept ® and Excelon ® ; treatments for Parkinson's Disease such as L-DOP A/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., Avonex ® and Rebif ® ), Copaxone ® , and mitoxantrone; treatments for asthma such as albuterol and Singulair ® ; agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-I RA, azathioprine, cyclophosphamide, and sulfasalazine;
• MS Multiple Sclerosis
• the invention comprises a method of inhibiting
• the invention comprises a method of inhibiting
• the invention comprises a method of treating or lessening the severity of a ROCK kinase-mediated condition or disease in a patient.
• ROCK-mediated condition or “disease”, as used herein, means any disease or other deleterious condition in which ROCK is known to play a role.
• ROCK- mediated condition or “disease” also means those diseases or conditions that are alleviated by treatment with a ROCK inhibitor.
• Such conditions include, without limitation, hypertension, angina pectoris, cerebrovascular contraction, asthma, peripheral circulation disorder, preterm labor, cancer, erectile dysfunction, atherosclerosis, spasm (cerebral vasospasm and coronary vasospasm), retinopathy (e.g., glaucoma), inflammatory disorders, autoimmune disorders, AE)S, osteoporosis, myocardial hypertrophy, ischemia/reperfusion-induced injury, and endothelial dysfunction.
• the present invention relates to a method for treating or lessening the severity of benign prostatic hyperplasia or diabetes.
• the method comprises the additional step of administering to said patient an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent,, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an antipsychotic agent, an agent for treating cardiovascular disease, an agent for treating destructive bone disorders, an agent for treating liver disease, an anti-viral agent, an agent for treating blood disorders, an agent for treating diabetes, or an agent for treating immunodeficiency disorders, wherein said additional therapeutic agent is appropriate for the disease being treated and said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.
• an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent,, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an antipsychotic agent, an agent for treating cardiovascular disease, an agent for treating destructive bone disorders, an agent for treating liver disease, an anti-viral agent, an agent for treating blood disorders,
• said disease, condition, or disorder is hypertension, cerebral vasospasm, coronary vasospasm, bronchial asthma, preterm labor, erectile dysfunction, glaucoma, vascular smooth muscle cell proliferation, myocardial hypertrophy, malignoma, ischemia/reperfusion-induced injury, endothelial dysfunction, Crohn's Disease, colitis, neurite outgrowth, Raynaud's Disease, angina pectoris, Alzheimer's disease, benign prostatic hyperplasia, cardiac hypertrophy, perivascular fibrosis or atherosclerosis.
• the present invention relates to a method for treating or lessening the severity of a cancer.
• the present invention relates to a method for treating or lessening the severity of a cancer selected from brain (gliomas), breast, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, prostate, sarcoma, or thyroid.
• the present invention relates to a method for treating or lessening the severity of pancreatic, prostate, or ovarian cancer.
• the invention provides a method of inhibiting
• JAK-mediated disease means any disease or other deleterious condition in which a JAK family kinase, in particular JAK2 or JAK3, is known to play a role.
• Such conditions include, without limitation, immune responses such as allergic or type I hypersensitivity reactions, asthma, autoimmune diseases such as transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis, and multiple sclerosis, neurodegenerative disorders such as familial amyotrophic lateral sclerosis
• FALS FALS
• solid and hematologic malignancies such as leukemias and lymphomas.
• the invention provides a method of treating or lessening the severity of a disease of condition selected from a proliferative disorder, a cardiac disorder, a neurodegenerative disorder, an autoimmune disorder, a condition associated with organ transplant, an inflammatory disorder, an immune disorder or an immunologically mediated disorder, comprising administering to said patient a compound or composition of the invention.
• the method comprises the additional step of administering to said patient an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, or an agent for treating immunodeficiency disorders, wherein said additional therapeutic agent is appropriate for the disease being treated and said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.
• an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, or an agent for treating immunodeficiency disorders
• the disease or disorder is allergic or type I hypersensitivity reactions, asthma, diabetes, Alzheimer's disease, Huntington's disease, Parkinson's disease, AIDS-associated dementia, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), multiple sclerosis (MS), schizophrenia, cardiomyocyte hypertrophy, reperfusion/ischemia, stroke, baldness, transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis, and multiple sclerosis, and solid and hematologic malignancies such as leukemias and lymphomas.
• said disease or disorder is asthma.
• said disease or disorder is transplant rejection.
• a compound or composition of this invention may be used to treat a myeloproliferative disorder.
• the myeloproliferative disorder is polycythemia vera, essential thrombocythemia, or chronic idiopathic myelofibrosis.
• the myeloproliferative disorder is myeloid metaplasia with myelofibrosis, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic eosinophilic leukemia, hypereosinophilic syndrome, systematic mast cell disease, atypical CML or juvenile myelomonocytic leukemia.
• an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of the aforementioned disorders.
• the compounds and compositions, according to the method of the present invention may be administered using any amount and any route of administration effective for treating or lessening the severity of the disorder or disease. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
• the methods of this invention comprise the additional step of separately administering to said patient an additional therapeutic agent.
• additional therapeutic agents When these additional therapeutic agents are administered separately they may be administered to the patient prior to, sequentially with or following administration of the compositions of this invention.
• the compounds of this invention or pharmaceutical compositions thereof may also be used for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts,. stents and catheters.
• an implantable medical device such as prostheses, artificial valves, vascular grafts,. stents and catheters.
• Vascular stents for example, have been used to overcome restenosis (re-narrowing of the vessel wall after injury).
• patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted effects may be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a compound of this invention.
• Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121.
• the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.
• the coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
• Implantable devices coated with a compound of this invention are another embodiment of the present invention.
• the compounds may also be coated on implantable medical devices, such as beads, or co-formulated with a polymer or other molecule, to provide a "drug depot", thus permitting the drug to be released over a longer time period than administration of an aqueous solution of the drug.
• the compounds of this invention may be prepared in general by methods known to those skilled in the art for analogous compounds or by those methods depicted in the Examples below. See, e.g., the examples described in WO 2005/095400, which is herein incorporated by reference in its entirety.
• the solution was diluted with water (400 mL), cooled to O 0 C and filtered.
• the solid dried in a vac oven at 50 0 C to provide 4.92 g of brown solid which was used without purification.
• the brown solid was dissolved in DMF (40 mL) cooled to 0 °C and treated with NaH (60% in oil, 750 mg) followed by addition of toluenesulfonyl chloride (3.92 g, 20.5 mmol). Additional portions of NaH (60% in oil, 2 x 750 mg) were added at 1 h intervals. After 4 h, EtOAc was added and the reaction was quenched with sat'd NaHCO 3 .
• the title compound (116) was prepared using method B to afford 0.7 mg as an off-white solid.
• the container was sealed and the reaction mixture was exposed to microwave irradiation for 30 min at 160 0 C.
• the resulting mixture was diluted in ethyl acetate, washed with water and dried over anhydrous Na 2 SO 4 .
• the crude material was purified by flash chromatography on silica gel, eluting with hexanes/ethyl acetate mixtures (90:10 to 60:40).
• the title compound J was isolated as a pale yellow solid (2.1 g, 50%).
• the reaction mixture was quenched with a solution of aqueous HCl 2M (10 mL) and stirred at room temperature for 1 h.
• the organic layer was then separated, washed with aqueous HCl 0.5 M, dried over anhydrous Na 2 SO 4 and the solvent removed under a stream of nitrogen.
• a second crop of desired product was obtained after neutralizing the aqueous layer with saturated solution of NaHCO 3 and extracting with ethyl acetate, followed by drying over anhydrous Na 2 SO 4 and removing the organic solvent under a stream of nitrogen.
• the title compound (M) was isolated as a white solid (1.27 g, 64%).
• the crude material was dissolved in DMSO and purified by reversed phase ⁇ PLC, eluting with Acetonitrile/water/l%TFA mixtures, yielding iV-(6-(l-tosyl-(lH- pyrrolo[2,3-b]pyridine ⁇ 4-yl)pyridin-2-yl)acetamine (R).
• R was dissolved in methanol and treated with NaOMe 0.5 M(1.5 mL). The resulting mixture was warmed at 60 0 C for 30 min.
• the crude was diluted in ethyl acetate, washed with saturated aqueous NaHCO 3 , dried over anhydrous Na 2 SO 4 , followed by removal of the solvent under reduced pressure.
• the crude oil was dissolved in DMSO (2 mL) and purified by reversed phase HPLC, eluting with acetonitrile/water/l%TFA mixtures.
• the title compound (98) was isolated after removing the solvents using a liophilizer (vacuum and heat lead to decomposition of the sample). (2.4 mg, 8%).
• the reaction was quenched with a saturated solution of NH 4 Cl, followed by aqueous NaHCO 3 .
• the crude reaction was diluted in diethyl ether, washed with brine, dried over anhydrous Na 2 SO 4 and the solvent was then removed under reduced pressure.
• the resulting material was purified by flash chromatography on silica gel, eluting with mixtures of dichloromethane/hexanes (2:1). The title compound U was isolated as a white solid (1.1 g, 51%).
• VV (0.075 g, 0.2 mmol) was dissolved in DMF under nitrogen.
• DIEA DIEA
• Method C was used in the case of aliphatic and liquid amines (Scheme 3), while Pd-catalyzed coupling was used for solid and aromatic amines (Scheme 4).
• the amide part on the indole nitrogen was hydrolysed selectively in presence of the amide on the piperidine /pyrrolidine nitrogen. [0385 ] Due to this formation of disubstituted products, removal of the tosyl group after reaction with acid chlorides was preferred.
• Acids could be coupled after Boc deprotection in the presence of tosyl group on the indole nitrogen but attemps to remove this protecting group were unsuccessful.
• the newly introduced amides were hydrolized. Products from 3,3,3- trifluoropropionic acid and cyanoacetic acid were obtained after deprotection of tosyl and Boc protecting groups in this order and then using a coupling reagent.
• Method C To D (20 mg, 0.086 mmol) was added amine (0.5 ml) in a pressure tube flushed with N 2 . The mixture was heated to 23O 0 C (bath temperature) for 24 h. The mixture was concentrated. Preparative HPLC provided 5-chloro-iV- cyclopentyl-lH-pyrrolo[2,3-b]pyridin-4-amine (7.4 mg) as the TFA salt. [0390] Method D: Pd(OAc) 2 (3.9 mg, 0.015mmol) and ( ⁇ )-BINAP (20 mg,
• Boc-NH- R compounds were treated with a standard solution 6N of HCl in IPA (1 mmol of compound in 4 mL), stirred 2 h at room temperature to remove Boc and isolated after the solvent was removed in vacuo.
• IPA a standard solution 6N of HCl in IPA (1 mmol of compound in 4 mL)
• triethylamine 3 eq
• the mixture was stirred for 10 min at room temperature. Water was added and the phases were separated. The organic layer was dried over sodium sulfate and the solvent was removed in vacuo.
• the amines were used without purification.
• R' compounds were obtained in 90% yield from E with JV-Boc-3- aminopyrrolidine or iV-Boc-3-aminopiperidme using method D. If needed, compound R' could be separated from BDSfAP impurities by chromatography eluting with CH 2 Cl 2 : EtOAc 20:1.
• a compound of formula S' (60 mg) was dissolved in a 2: 1 THF:MeOH mixture (4 ml) and 6N aq KOH solution (0.8 ml) was added. After 1 h at room temperature, solvents were evaporated and the mixture taken up in ethyl acetate, washed with brine, dried (Na 2 SO 4 ), filtrated and concentrated. The product could be purified by column chromatography (heptane:EtOAc 1:2 mixture). The product was then dissolved in dichloromethane (3 ml) and 5 N HCl in 2-propanol (0.7 ml) was added. After 1 h at room temperature the mixture was evaporated to dryness to give a white salt.
• the crude compound K was purified by column chromatography (silica gel 100-200 mesh, MeOHZCHCl 3 ⁇ l%MeOH/CHCl 3 ).
• the Boc group from K" may be removed by standard procedures to obtain L".
• Example 2 NMR and Mass Spectrometry of Compounds
• Analytical data for certain compounds of the present invention was collected and recorded.
• proton NMR was collected using a Bruker AMX 500 instrument and appropriate solvent.
• the LC/MS method used a Hypersil BDS Cl 8 5 micron 2.1 x 50 mm column with a flow rate of l.Oml/min with an appropriate gradient.
• Mass spectrometer samples were analyzed on a MicroMass ZQ or Quattro II mass spectrometer operated in single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using flow injection (FIA) or chromatography. Mobile phase for all mass spectrometer analysis consisted of acetonitrile-water mixtures or TFA in some instances.
• Table 3 below depicts exemplary LC mass spectral data (LC/MS), retention time (RT) and 1 H-NMR data for certain compounds of the present invention, wherein compound numbers in Table 3 correspond to the compounds depicted in Table 1 (empty cells indicate that the test was not performed): Table 3
• Table 4 below depicts exemplary LC/MS, RT and 1 H-NMR data for certain compounds of the present invention, wherein compound numbers in Table 4 correspond to the compounds depicted in Table 2 (empty cells indicate that the test was not performed). For the compounds in Table 4, proton NMR was collected using as indicated. Table 4
• 1.5 ⁇ l of DMSO stock containing serial dilutions of the compound of the present invention (concentrations ranging from 10 ⁇ M to 2.6nM) was placed in a 96 well plate.
• 50 ⁇ l of Solution 1 100 mM HEPES (pH 7.5), 10 mM MgCl 2 , 26 mM [ ⁇ - 33 P] ATP was added to the plate.
• the reaction was initiated by addition of 50 ⁇ l of Solution 2 (100 mM HEPES (pH 7.5), 10 mM MgCl 2 , 4 mM DTT, 54 mM MBP and 10 nM ROCK).
• Tables 5 and 6 depict enzyme inhibition data (Ki) for certain exemplary compounds.
• Compound numbers in Table 5 correspond to those compounds depicted in Table 1, while compound numbers in Table 6 correspond to those compounds depicted in Table 2.
• “A” represents a K 1 of less than 0.5 ⁇ M
• “B” represents a Kj of between 0.5 and 5.0 ⁇ M
• “C” represents a Kj greater than 5.0 ⁇ M for the indicated enzyme (for Table 6, "C” represents a Ki greater than 4.0 ⁇ M for ROCK I).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Immunology (AREA)
• Physical Education & Sports Medicine (AREA)
• Pulmonology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Virology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Oncology (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Rheumatology (AREA)
• Psychiatry (AREA)
• Dermatology (AREA)
• Reproductive Health (AREA)
• Gynecology & Obstetrics (AREA)
• Communicable Diseases (AREA)
• Hematology (AREA)
• Psychology (AREA)
• Pregnancy & Childbirth (AREA)
• Obesity (AREA)
• Emergency Medicine (AREA)
• Pain & Pain Management (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (1)

Family

ID=36940144

Family Applications (1)

Country Status (16)

Cited By (126)

Families Citing this family (52)

Citations (19)

Family Cites Families (37)

• 2006
  • 2006-05-22 WO PCT/US2006/019711 patent/WO2006127587A1/en not_active Ceased
  • 2006-05-22 CN CN2006800263918A patent/CN101228161B/zh not_active Expired - Fee Related
  • 2006-05-22 AU AU2006251623A patent/AU2006251623A1/en not_active Abandoned
  • 2006-05-22 MX MX2007014619A patent/MX2007014619A/es not_active Application Discontinuation
  • 2006-05-22 KR KR1020077029764A patent/KR20080016659A/ko not_active Ceased
  • 2006-05-22 EP EP10188700A patent/EP2354140A1/en not_active Withdrawn
  • 2006-05-22 ES ES06770824T patent/ES2380795T3/es active Active
  • 2006-05-22 ZA ZA200710379A patent/ZA200710379B/xx unknown
  • 2006-05-22 JP JP2008512591A patent/JP2008545660A/ja active Pending
  • 2006-05-22 NZ NZ564065A patent/NZ564065A/en not_active IP Right Cessation
  • 2006-05-22 RU RU2007147455/04A patent/RU2435769C2/ru not_active IP Right Cessation
  • 2006-05-22 EP EP10188694A patent/EP2354139A1/en not_active Withdrawn
  • 2006-05-22 AT AT06770824T patent/ATE540948T1/de active
  • 2006-05-22 EP EP06770824A patent/EP1881983B1/en not_active Not-in-force
  • 2006-05-22 CA CA002609126A patent/CA2609126A1/en not_active Abandoned
  • 2006-05-22 US US11/438,748 patent/US8921376B2/en not_active Expired - Fee Related
• 2007
  • 2007-11-18 IL IL187438A patent/IL187438A0/en unknown
  • 2007-12-18 NO NO20076502A patent/NO20076502L/no not_active Application Discontinuation
• 2009
  • 2009-05-21 JP JP2009123635A patent/JP2009179644A/ja active Pending
• 2011
  • 2011-08-11 RU RU2011133825/04A patent/RU2011133825A/ru not_active Application Discontinuation
• 2013
  • 2013-09-24 JP JP2013196681A patent/JP2013253114A/ja active Pending

Patent Citations (19)

Non-Patent Citations (1)